Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 14/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.56 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD3 | P35462 | 4/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arbutamine SCHEMBL3699485 | 1.00 | ADRB2 (0.61) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL29929016 | 1.00 | ADRB2 (0.61) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL20769823 | 1.00 | ADRB2 (0.61) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL29390265 | 1.00 | ADRB2 (0.61) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL7295080 | 0.99 | ADRB2 (0.60) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL40757 | 0.99 | ADRB2 (0.60) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL4327619 | 0.97 | ADRB2 (0.59) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Arbutamine SCHEMBL7870502 | 0.94 | ADRB2 (0.58) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Hexoprenaline SCHEMBL121449 | 0.85 | ADRB2 (0.72) | ADRB2ADRB1ADRB3DRD2DRD3 | |
| Hexoprenaline SCHEMBL32668781 | 0.85 | ADRB2 (0.72) | ADRB2ADRB1ADRB3DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 952 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025265094-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-12-26 | — | — | WO | claimed |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-12-02 | — | — | US | claimed |
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | SERINA THERAPEUTICS (AL), INC. (US) | 2025-08-12 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| US-20240398729-A1 | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240316208-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | SERINA THERAPEUTICS (AL), INC. (US) | 2024-09-26 | — | — | US | claimed |
| US-20020061835-A1 | Administering a drug to a human which is pharmaceutically effective to regulate at least one of the blood parameters used to adjust distribution of the drug through the bloodstream | RHEOLOGICS, INC. | 2002-05-23 | — | — | US | claimed |
| US-20020032149-A1 | Monitoring blood flow parameter of bloodstream, administering substance to organism such that an amount of substance enters bloodstream; distributing portion of amount ofsubstance target within organism | RHEOLOGICS, INC. | 2002-03-14 | — | — | US | claimed |
| US-6339716-B1 | Method for determining viability of a myocardial segment | BIOENERGY INC. | 2002-01-15 | — | — | US | claimed |
| US-20010044584-A1 | In vivo delivery methods and compositions | RHEOLOGICS, INC. | 2001-11-22 | — | — | US | claimed |
| EP-1098641-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | Texas Pharmaceuticals, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2001021218-A2 | METHOD FOR DETERMINING VIABILITY OF A MYOCARDIAL SEGMENT | BIOENERGY INC. (US) | 2001-03-29 | — | — | WO | claimed |
| EP-1067970-A2 | DIAGNOSTIC IMAGING OF VASCULAR ABNORMALITIES USING VASOMODIFICATION | NYCOMED IMAGING AS (NO) | 2001-01-17 | — | — | EP | claimed |
| WO-2000006143-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | TEXAS PHARMACEUTICALS, INC. (US) | 2000-02-10 | — | — | WO | claimed |
| WO-1999049899-A2 | DIAGNOSTIC IMAGING OF VASCULAR ABNORMALITIES USING VASOMODIFICATION | NYCOMED IMAGING AS (NO) | 1999-10-07 | — | — | WO | claimed |
| WO-1992020324-A1 | POLYURETHANE HYDROGEL COMPOSITIONS FOR IONTOPHORETIC DRUG DELIVERY | GENSIA PHARMACEUTICALS, INC. (US) | 1992-11-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383625-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | ADRB2 1728/4885ADRB1 2274/4885ADRB3 1191/4885 |
| US-12485181-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, CYP2C19, CYP3A7 | ADRB2 1814/4885ADRB1 2498/4885ADRB3 1120/4885 |
| US-12383626-B2 | Polyoxazoline-drug conjugates with novel pharmacokinetic properties | CYP3A5, SPOP, CYP2C19 | ADRB2 1728/4885ADRB1 2274/4885ADRB3 1191/4885 |
| US-20240316208-A1 | POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIES | CYP3A5, SPOP, CYP2C19 | ADRB2 1728/4885ADRB1 2274/4885ADRB3 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.